Secondly, while CD4+ T cells, NK cells, and γδ T cells have been identified as key effector cells for ICB treatment in B2M-deficient cancers, the underlying mechanisms by which these cells mediate their cytotoxic effects remain to be fully elucidated. This evidence concerns the gene CD4 and cancer.